Influx Healthtech Limited is set to open its Initial Public Offering (IPO) on June 18, 2025, with the issue closing on June 20, 2025. This is a Book Built Issue through which the company aims to raise approximately ₹58.57 crores. The IPO consists of a fresh issue of ₹48.00 crores and an offer for sale of up to 11,00,400 equity shares, each with a face value of ₹10. The price band for the IPO is fixed between ₹91 and ₹96 per share.

The issue allocation is divided into 50% for Qualified Institutional Buyers (QIB), 15% for High Net-worth Individuals (HNI), and 35% for retail investors. The shares are expected to be listed on the NSE on June 25, 2025, and the allotment is likely to be finalized by June 23, 2025.

On the financial front, Influx Healthtech reported a revenue of ₹104.99 crores in FY 2025, compared to ₹100.10 crores in FY 2024. Net profit also increased to ₹13.37 crores in FY 2025 from ₹11.22 crores the previous year, indicating steady financial growth. Based on the company’s performance and market position, the IPO appears suitable for long-term investors looking for exposure in the healthtech and contract manufacturing space.

Founded in 2020, Influx Healthtech Limited is a prominent healthcare-focused company specializing in contract manufacturing services. As a trusted Contract Development and Manufacturing Organization (CDMO), the company provides end-to-end solutions to clients across various sectors. Its manufacturing facilities, located in Thane, Maharashtra, span approximately 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft., and are equipped to maintain high standards of safety, quality, and regulatory compliance.

Influx Healthtech operates in multiple product categories, including dietary and nutritional supplements, cosmetics, ayurvedic and herbal products, veterinary feed supplements, and homecare items. The company serves an impressive roster of clients such as Bling Brands, Pursuit of Wellness, Aarkios Health, HSHS Nutraceuticals Limited, Novus Life Science, Bruder Life Science, Fredun Pharmaceuticals, and BigFlex Lifescience. As of now, the company employs 165 permanent staff, supporting its mission to deliver reliable, high-quality contract manufacturing solutions.

Objects of the Issue (JNK India IPO Objectives)

• Capital expenditure for establishing a new manufacturing facility for the Nutraceutical Division
• Capital expenditure for setting up a manufacturing unit for the Veterinary Food Division
• Procurement of machinery for the Homecare and Cosmetic Division
• General corporate purposes

JNK India IPO Review (Apply)

• BP Wealth
• Canara Bank
• Capital Market
• Choice Broking
• DRChoksey
• FinServ
• Emkay Global
• Geojit
• Hem Securities
• ICICIdirect
• IDBI Capital
• Marwadi Shares
• Nirmal Bang
• Reliance Securities
• SBI
• CAP Securities
• Sharekhan
• SMC Global
• Sushil Finance
• Swastika Investmart
• Ventura Securities

Financial Report

Financial Report